These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 15221819)

  • 1. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
    Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
    J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
    Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
    Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
    Preda A; Novikov V; Möglich M; Turetschek K; Shames DM; Brasch RC; Cavagna FM; Roberts TP
    J Magn Reson Imaging; 2004 Nov; 20(5):865-73. PubMed ID: 15503324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
    Fournier LS; Novikov V; Lucidi V; Fu Y; Miller T; Floyd E; Shames DM; Brasch RC
    Radiology; 2007 Apr; 243(1):105-11. PubMed ID: 17329684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.
    Gossmann A; Helbich TH; Mesiano S; Shames DM; Wendland MF; Roberts TP; Ferrara N; Jaffe RB; Brasch RC
    Am J Obstet Gynecol; 2000 Oct; 183(4):956-63. PubMed ID: 11035346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
    Turetschek K; Preda A; Floyd E; Shames DM; Novikov V; Roberts TP; Wood JM; Fu Y; Carter WO; Brasch RC
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):448-55. PubMed ID: 12722742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights.
    Cheng HL; Wallis C; Shou Z; Farhat WA
    J Magn Reson Imaging; 2007 Jan; 25(1):137-45. PubMed ID: 17139634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations.
    Raatschen HJ; Fu Y; Shames DM; Wendland MF; Brasch RC
    Invest Radiol; 2006 Dec; 41(12):860-7. PubMed ID: 17099424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice.
    de Lussanet QG; Beets-Tan RG; Backes WH; van der Schaft DW; van Engelshoven JM; Mayo KH; Griffioen AW
    Eur J Cancer; 2004 May; 40(8):1262-8. PubMed ID: 15110892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.
    Reichert F; Barak V; Tarshis M; Prindull G; Tarshis E; Ben-Ishay Z
    Eur J Haematol; 2005 Jul; 75(1):41-6. PubMed ID: 15946309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
    Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
    Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis.
    Zhang XM; Yu D; Zhang HL; Dai Y; Bi D; Liu Z; Prince MR; Li C
    J Magn Reson Imaging; 2008 Jun; 27(6):1309-16. PubMed ID: 18504761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
    Li KL; Wilmes LJ; Henry RG; Pallavicini MG; Park JW; Hu-Lowe DD; McShane TM; Shalinsky DR; Fu YJ; Brasch RC; Hylton NM
    J Magn Reson Imaging; 2005 Oct; 22(4):511-9. PubMed ID: 16161072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer.
    de Lussanet QG; Backes WH; Griffioen AW; Padhani AR; Baeten CI; van Baardwijk A; Lambin P; Beets GL; van Engelshoven JM; Beets-Tan RG
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1309-15. PubMed ID: 16125874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer.
    Su MY; Cheung YC; Fruehauf JP; Yu H; Nalcioglu O; Mechetner E; Kyshtoobayeva A; Chen SC; Hsueh S; McLaren CE; Wan YL
    J Magn Reson Imaging; 2003 Oct; 18(4):467-77. PubMed ID: 14508784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.
    Padhani AR
    J Magn Reson Imaging; 2002 Oct; 16(4):407-22. PubMed ID: 12353256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.